| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8632861 | Metabolism | 2018 | 32 Pages |
Abstract
In T2D patients with comorbidities, METâ¯+â¯DPP4i treatment is associated with lower risks of CVD events and all-cause mortality compared with METâ¯+â¯SU, independent of type or number of comorbidities. A more complex comorbid status further increases this effect.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Yeon Young Cho, Sung-Il Cho,